Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247- 4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/MRN ...

Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=91974&from=4 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant ...

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. Investors who purchased the Company's securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 5, 2024. The class, in this case, has not yet been ...

NEW YORK, July 19, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) and reminds investors of the August 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false an ...

Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=90884&from=4 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant ...

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit. https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=90732&wire=3 WHAT'S NEXT? If you suffered a loss in Marinus during the relevant time frame, you have until August 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't requir ...

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=90492&from=3 C ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. WHAT TO DO NEXT: To join the Marinus class action, go to https://rosenlegal.com/submit-form/? case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenl ...

NEW YORK, July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=90343&from=4 CLASS ...

NEW YORK, July 11, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocke ...